A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity

Research output: Contribution to journalReview article

31 Citations (Scopus)

Abstract

Even in the presence of excess glucose, the proximal renal tubules continue to resorb more glucose. Sodium glucose cotransporter 2 (SGLT2) inhibitors are drugs that control this “greed” (H. Ito, Keio University, Japan). Negative feedback mechanisms maintain homeostasis for various physiological functions. However, there is no negative feedback mechanism for resorption of glucose by the proximal renal tubules. When food was scarce during human evolution, not limiting nutrient reabsorption was advantageous for survival, but the opposite is true in the era of satiation. SGLT2 inhibitors were designed to apply the brakes to uncontrolled glucose resorption by the kidneys in patients with diabetes. It has become clear that SGLT2 inhibitors not only improve the blood glucose level, but also show cardiovascular and renal protective effects irrespective of the reduction of blood glucose in patients with type 2 diabetes mellitus (T2DM). The mechanisms underlying cardiovascular and renal protection by SGLT2 inhibitors in T2DM are complex, multifactorial, and not completely understood. A common, and perhaps underappreciated, feature of T2DM is chronic activation of the sympathetic nervous system. This elevation of sympathetic activity contributes to the development of hypertension. It is also associated with a poor prognosis and with increased cardiovascular and renal morbidity/mortality independently of the effect on blood pressure. This review discusses novel insights into cardiovascular protection by SGLT2 inhibitors, focusing on the interaction between SGLT2 and the sympathetic nervous system.

Original languageEnglish
Pages (from-to)471-476
Number of pages6
JournalJournal of Cardiology
Volume71
Issue number5
DOIs
Publication statusPublished - 2018 May 1

Fingerprint

Sodium-Glucose Transport Proteins
Heart Failure
Pharmaceutical Preparations
Type 2 Diabetes Mellitus
Kidney
Glucose
Proximal Kidney Tubule
Sympathetic Nervous System
Blood Glucose
Satiation
Food
Drug and Narcotic Control
Japan
Homeostasis
Blood Pressure
Hypertension
Morbidity
Survival
Mortality

Keywords

  • Cardiovascular protection
  • Heart failure
  • Sodium glucose cotransporter 2 inhibitor
  • Sympathetic overactivity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

A new class of drugs for heart failure : SGLT2 inhibitors reduce sympathetic overactivity. / Sano, Motoaki.

In: Journal of Cardiology, Vol. 71, No. 5, 01.05.2018, p. 471-476.

Research output: Contribution to journalReview article

@article{ef151f4943b746378ab92d3f2a22035f,
title = "A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity",
abstract = "Even in the presence of excess glucose, the proximal renal tubules continue to resorb more glucose. Sodium glucose cotransporter 2 (SGLT2) inhibitors are drugs that control this “greed” (H. Ito, Keio University, Japan). Negative feedback mechanisms maintain homeostasis for various physiological functions. However, there is no negative feedback mechanism for resorption of glucose by the proximal renal tubules. When food was scarce during human evolution, not limiting nutrient reabsorption was advantageous for survival, but the opposite is true in the era of satiation. SGLT2 inhibitors were designed to apply the brakes to uncontrolled glucose resorption by the kidneys in patients with diabetes. It has become clear that SGLT2 inhibitors not only improve the blood glucose level, but also show cardiovascular and renal protective effects irrespective of the reduction of blood glucose in patients with type 2 diabetes mellitus (T2DM). The mechanisms underlying cardiovascular and renal protection by SGLT2 inhibitors in T2DM are complex, multifactorial, and not completely understood. A common, and perhaps underappreciated, feature of T2DM is chronic activation of the sympathetic nervous system. This elevation of sympathetic activity contributes to the development of hypertension. It is also associated with a poor prognosis and with increased cardiovascular and renal morbidity/mortality independently of the effect on blood pressure. This review discusses novel insights into cardiovascular protection by SGLT2 inhibitors, focusing on the interaction between SGLT2 and the sympathetic nervous system.",
keywords = "Cardiovascular protection, Heart failure, Sodium glucose cotransporter 2 inhibitor, Sympathetic overactivity",
author = "Motoaki Sano",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.jjcc.2017.12.004",
language = "English",
volume = "71",
pages = "471--476",
journal = "Journal of cardiography. Supplement",
issn = "0914-5087",
publisher = "Japanese College of Cardiology (Nippon-Sinzobyo-Gakkai)",
number = "5",

}

TY - JOUR

T1 - A new class of drugs for heart failure

T2 - SGLT2 inhibitors reduce sympathetic overactivity

AU - Sano, Motoaki

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Even in the presence of excess glucose, the proximal renal tubules continue to resorb more glucose. Sodium glucose cotransporter 2 (SGLT2) inhibitors are drugs that control this “greed” (H. Ito, Keio University, Japan). Negative feedback mechanisms maintain homeostasis for various physiological functions. However, there is no negative feedback mechanism for resorption of glucose by the proximal renal tubules. When food was scarce during human evolution, not limiting nutrient reabsorption was advantageous for survival, but the opposite is true in the era of satiation. SGLT2 inhibitors were designed to apply the brakes to uncontrolled glucose resorption by the kidneys in patients with diabetes. It has become clear that SGLT2 inhibitors not only improve the blood glucose level, but also show cardiovascular and renal protective effects irrespective of the reduction of blood glucose in patients with type 2 diabetes mellitus (T2DM). The mechanisms underlying cardiovascular and renal protection by SGLT2 inhibitors in T2DM are complex, multifactorial, and not completely understood. A common, and perhaps underappreciated, feature of T2DM is chronic activation of the sympathetic nervous system. This elevation of sympathetic activity contributes to the development of hypertension. It is also associated with a poor prognosis and with increased cardiovascular and renal morbidity/mortality independently of the effect on blood pressure. This review discusses novel insights into cardiovascular protection by SGLT2 inhibitors, focusing on the interaction between SGLT2 and the sympathetic nervous system.

AB - Even in the presence of excess glucose, the proximal renal tubules continue to resorb more glucose. Sodium glucose cotransporter 2 (SGLT2) inhibitors are drugs that control this “greed” (H. Ito, Keio University, Japan). Negative feedback mechanisms maintain homeostasis for various physiological functions. However, there is no negative feedback mechanism for resorption of glucose by the proximal renal tubules. When food was scarce during human evolution, not limiting nutrient reabsorption was advantageous for survival, but the opposite is true in the era of satiation. SGLT2 inhibitors were designed to apply the brakes to uncontrolled glucose resorption by the kidneys in patients with diabetes. It has become clear that SGLT2 inhibitors not only improve the blood glucose level, but also show cardiovascular and renal protective effects irrespective of the reduction of blood glucose in patients with type 2 diabetes mellitus (T2DM). The mechanisms underlying cardiovascular and renal protection by SGLT2 inhibitors in T2DM are complex, multifactorial, and not completely understood. A common, and perhaps underappreciated, feature of T2DM is chronic activation of the sympathetic nervous system. This elevation of sympathetic activity contributes to the development of hypertension. It is also associated with a poor prognosis and with increased cardiovascular and renal morbidity/mortality independently of the effect on blood pressure. This review discusses novel insights into cardiovascular protection by SGLT2 inhibitors, focusing on the interaction between SGLT2 and the sympathetic nervous system.

KW - Cardiovascular protection

KW - Heart failure

KW - Sodium glucose cotransporter 2 inhibitor

KW - Sympathetic overactivity

UR - http://www.scopus.com/inward/record.url?scp=85044521391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044521391&partnerID=8YFLogxK

U2 - 10.1016/j.jjcc.2017.12.004

DO - 10.1016/j.jjcc.2017.12.004

M3 - Review article

C2 - 29415819

AN - SCOPUS:85044521391

VL - 71

SP - 471

EP - 476

JO - Journal of cardiography. Supplement

JF - Journal of cardiography. Supplement

SN - 0914-5087

IS - 5

ER -